Relmada Therapeutics Inc (RLMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has a cash flow conversion efficiency ratio of -0.169x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.60 Million) by net assets ($86.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Relmada Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Relmada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Relmada Therapeutics Inc for net asset value and shareholders' equity analysis.
Relmada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relmada Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kossan Rubber Industries Bhd
KLSE:7153
|
0.021x |
|
Nanjing Hongbaoli Corp Ltd
SHE:002165
|
-0.026x |
|
OCI NV
AS:OCI
|
-0.021x |
|
Shandong Xiantan Co Ltd
SHE:002746
|
0.052x |
|
Ferroglobe PLC
NASDAQ:GSM
|
-0.011x |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
0.071x |
|
Logistea AB Series B
ST:LOGI-B
|
0.003x |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
0.024x |
Annual Cash Flow Conversion Efficiency for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RLMD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.51 Million | $-45.79 Million | -0.529x | +63.68% |
| 2024-12-31 | $35.52 Million | $-51.76 Million | -1.457x | -140.74% |
| 2023-12-31 | $85.36 Million | $-51.66 Million | -0.605x | +18.12% |
| 2022-12-31 | $140.44 Million | $-103.80 Million | -0.739x | -67.55% |
| 2021-12-31 | $208.26 Million | $-91.87 Million | -0.441x | -67.49% |
| 2020-12-31 | $105.58 Million | $-27.81 Million | -0.263x | -251866.34% |
| 2019-12-31 | $115.68 Million | $-12.09K | 0.000x | -100.01% |
| 2018-12-31 | $-5.51 Million | $-6.00 Million | 1.089x | +124.59% |
| 2017-12-31 | $1.46 Million | $-6.47 Million | -4.428x | -137.26% |
| 2016-12-31 | $7.04 Million | $-13.14 Million | -1.866x | -1.33% |
| 2015-12-31 | $8.81 Million | $-16.23 Million | -1.842x | 0.00% |
| 2014-12-31 | $8.81 Million | $-16.23 Million | -1.842x | -191.19% |
| 2014-06-30 | $-1.11 Million | $-2.24 Million | 2.020x | +18788.61% |
| 2013-12-31 | $-1.11 Million | $-11.86K | 0.011x | +101.61% |
| 2012-12-31 | $11.36K | $-7.57K | -0.666x | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more